1 – 20 of 20
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis : A population-based cohort study
(
- Contribution to journal › Article
- 2019
-
Mark
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis : unpredictable, but predictive of renal outcome
(
- Contribution to journal › Article
- 2017
-
Mark
Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides
(
- Contribution to journal › Article
-
Mark
Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
(
- Contribution to journal › Article
- 2015
-
Mark
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.
(
- Contribution to journal › Article
-
Mark
Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
(
- Contribution to journal › Article
- 2014
-
Mark
Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
- 2013
-
Mark
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
(
- Contribution to journal › Article
-
Mark
Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al Reply
(
- Contribution to journal › Letter
- 2012
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
-
Mark
Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article
- 2011
-
Mark
Long-term patient survival in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
The prognostic value of BVAS and VDI in ANCA-AAV
2011) 15th International Vasculitis/ANCA Workshop In Clinical and Experimental Immunology 164(Suppl. 1). p.121-121(
- Contribution to journal › Published meeting abstract
-
Mark
A Model to Predict Cardiovascular Events in Patients With Newly Diagnosed Wegener's Granulomatosis and Microscopic Polyangiitis
(
- Contribution to journal › Article
-
Mark
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
(
- Contribution to journal › Article
- 2010
-
Mark
A Model To Predict Cardiovascular Events In Patients With Newly Diagnosed Wegener'S Granulmoatosis And Microscopic Polyangiitis
2010) Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British-Health-Professional-in-Rheumatology In Rheumatology 49. p.124-124(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Long-term survival of ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictors of long-term (>= 5 year) renal survival in 535 patients with ANCA-associated vasculitis
(
- Contribution to journal › Published meeting abstract